Company intelligence / Profile preview
Tecnimede
- Ownership
- Private
- Employees
- ~700
- Development stage
- Commercial
Overview
Tecnimede has a broad commercial portfolio of over +130 products marketed in more than100 countries. The company develops both generic medicines and innovative fixed-dose combinations/new chemical entities. Its R&D activities include preclinical studies through Phase II/III clinical trials for select programs. It has a strong focus on cardiovascular/metabolic/CNS/infectious disease areas.[1][2][5][6]
- Therapeutic areas
- Metabolic Disorders
- Modalities
- Small molecules (generics and new chemical entities)[8]Fixed-dose combinations[8]Modified release formulations[8]Sterile forms[8]
- Industry
- Pharma
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Tecnimede.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tecnimede.